New Dengue Vaccine Suspended in Brazil After Severe Adverse Event Reports
Brazil’s Ministry of Health and the National Health Surveillance Agency (ANVISA) suspended a mass vaccination campaign using a new dengue vaccine developed by a Brazilian biomedical research center after severe adverse events, including deaths, were associated with certain batches of the vaccine. Authorities have opened an investigation into the incidents while continuing to assess the […]
WHO Prequalifies Takeda’s Qdenga Dengue Vaccine
On May 10, 2024, the World Health Organization (WHO) granted prequalification status to the Qdenga (TAK-003) dengue vaccine, developed by Takeda Pharmaceutical Company Ltd. of Tokyo, Japan. The live attenuated virus vaccine is recommended to be given in two doses three months apart to children six to 16 years old living in areas where dengue […]